UThymoKidney by United Therapeutics: status and timeline

Milestones

No announced next step

First UThymoKidney transplantApr 2024Complete.
Two-month normal organ function reportedJun 2024Complete.

Most important updates

Revivicor performs first UThymoKidney xenotransplant combining kidney and thymusApr 2024

Current obstacles

Thymic function in adult recipientsThymic tissue can regenerate immune competence, but success in adult transplant recipients with impaired immune systems is unproven.

Physics limits

Single-edit rejection riskA single genetic modification leaves multiple rejection pathways intact; durability depends on immunosuppression rather than extensive genetic engineering.

How it works

2 parts

Minimal genetic modification

Single critical edit

A simplified approach with one strategic genetic change, aiming for rapid immune acceptance and thymic function to assist immune reconstitution.

Dual organ support

Kidney and thymus from same pig

Provides both immediate renal replacement and longer-term immune reconstitution through thymic T-cell development.

Spec sheet

Spec	UThymoKidney
Total gene edits	1 edit (single-gene)^R (reported)
Organs transplanted	Kidney + Thymus^R (reported)

^R reported by the company

Papers & demos

1 item

Apr 2024demo
First successful UThymoKidney transplant (combined single-gene kidney and thymus) (opens businesswire.com)Exploration of dual-organ xenotransplant to combine renal replacement with immune reconstitution.

Update log

1 update

Apr 2024

Major: Revivicor performs first UThymoKidney xenotransplant combining kidney and thymusPressTest

About United Therapeutics

The team behind UThymoKidney

United Therapeutics

Xenotransplant, gene-edited pig organs, UKidney UHeart, Revivicor

United Therapeutics develops pig-organ xenotransplants via Revivicor for end-stage renal and cardiac disease. Programs include UKidney, UHeart, and UThymoKidney.

United Therapeutics acquired xenotransplant pioneer Revivicor in 2011.
December 2024: First UKidney transplant performed under FDA compassionate-use authorization.
Three programs: UKidney and UHeart (10 edits each), UThymoKidney (single-gene); trials planned 2025–2026.

unither.com (opens unither.com)Company profile →

Founded: 199630 yrs
Headquarters: United States
Status: Public
Listed: UTHR (opens google.com)NASDAQ
Valuation: $24Best. market capOct 2026estimate
Last round: Founded1996
Works in: BiotechCell & organ therapies
Coverage: 3 programs · 5 updateslatest 1 Feb 2025checked 10 Oct
Partners: NYU Langone Health (opens nyulangone.org)FDA (opens fda.gov)Revivicor, Inc. (opens revivicor.com)
People: Martine Rothblatt (opens en.wikipedia.org)Founder, Chairperson, and Chief Executive Officer

Spec

UThymoKidney

Total gene edits

1 edit (single-gene)^R (reported)

Organs transplanted

Kidney + Thymus^R (reported)